Cetrotide Европейски съюз - български - EMA (European Medicines Agency)

cetrotide

merck europe b.v. - cetrorelix (as acetate) - ovulation; ovulation induction - Хипофизни и хипоталамични хормони и аналози - Предотвратяване на преждевременната овулация при пациенти, подложени на контролирана овариална стимулация, последвана от ооцитна селекция и асистирана репродуктивна техника. В клинични проучвания, cetrotide се използва човешкият менопаузальный гонадотропин (hmg), обаче, ограничен опит в прилагането на рекомбинантен фоликулостимулиращ (fsh) са предложили еднаква ефективност.

Degarelix Accord Европейски съюз - български - EMA (European Medicines Agency)

degarelix accord

accord healthcare s.l.u. - degarelix acetate - Простатни неоплазми - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

Camcevi Европейски съюз - български - EMA (European Medicines Agency)

camcevi

accord healthcare s.l.u. - leuprorelin mesilate - Простатни неоплазми - Ендокринна терапия - camcevi is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.

Firmagon Европейски съюз - български - EMA (European Medicines Agency)

firmagon

ferring pharmaceuticals a/s - дегареликс - Простатни неоплазми - Ендокринна терапия - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

Lutrate Depot 22,5 mg powder and solvent for prolonged - release suspension for injection България - български - Изпълнителна агенция по лекарствата

lutrate depot 22,5 mg powder and solvent for prolonged - release suspension for injection

csc pharmaceuticals handels gmbh - Лейпрорелин - 22,5 mg powder and solvent for prolonged - release suspension for injection

Lutrate Depot 3,75 mg powder and solvent for prolonged - release suspension for injection България - български - Изпълнителна агенция по лекарствата

lutrate depot 3,75 mg powder and solvent for prolonged - release suspension for injection

csc pharmaceuticals handels gmbh - Лейпрорелин - 3,75 mg powder and solvent for prolonged - release suspension for injection